Search

Global Computational Biology & Digital Sciences

Discover how we play a vital role in identifying new drugs and how our work results in breakthrough therapies.

Boehringer-Ingelheim's-half-year-figures-2021

Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

EMPA-KIDNEY trial early stop due to positive efficacy

EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy

Ileitis prevention vaccination Lawsonia intracellularis pig

Cause, impact and prevention: Learn the essentials about Ileitis

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.

Phase II trial results in people living with obesity or overweight

Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas

Tackling NCDs through innovation AND collaboration

Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Phase II clinical trial weight loss results

Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)

Survey with Ipsos to gain insights human-animal bond

Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.

Boehringer Ingelheim half-year results 2023

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

EMA filing acceptance and validation for spesolimab

The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease